Covid-19 vaccine boosters could mean billions for drugmakers
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Sunday
August 14, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
SUNDAY, AUGUST 14, 2022
Covid-19 vaccine boosters could mean billions for drugmakers

Coronavirus chronicle

UNB/AP
26 September, 2021, 11:45 am
Last modified: 26 September, 2021, 03:38 pm

Related News

  • North Korea lifts mask mandate, distancing rules after declaring Covid victory
  • Bangladesh logs 1 death, 214 Covid cases in 24 hours
  • S Korea expresses regret over N Korea's 'groundless claim' over Covid, threats
  • Nepal battles 'Twindemic' as swine flu wreaks havoc amid rising Covid cases
  • 1 Covid death, 198 cases reported in a day

Covid-19 vaccine boosters could mean billions for drugmakers

Wall Street is taking notice. The average forecast among analysts for Moderna’s 2022 revenue has jumped 35% since President Joe Biden laid out his booster plan in mid-August

UNB/AP
26 September, 2021, 11:45 am
Last modified: 26 September, 2021, 03:38 pm
In this March 2021 photo provided by Pfizer, a technician works on a line for packaging preparation for the Pfizer-BioNTech Covid-19 vaccine at the company's facility in Puurs, Belgium. Billions more in profits are at stake for some vaccine makers as the U.S. moves toward dispensing Covid-19 booster shots to shore up Americans' protection against the virus. Photo :AP via UNB
In this March 2021 photo provided by Pfizer, a technician works on a line for packaging preparation for the Pfizer-BioNTech Covid-19 vaccine at the company's facility in Puurs, Belgium. Billions more in profits are at stake for some vaccine makers as the U.S. moves toward dispensing Covid-19 booster shots to shore up Americans' protection against the virus. Photo :AP via UNB

Billions more in profits are at stake for some vaccine makers as the US moves toward dispensing Covid-19 booster shots to shore up Americans' protection against the virus.

How much the manufacturers stand to gain depends on how big the rollout proves to be.

US health officials late on Thursday endorsed booster shots of the Pfizer vaccine for all Americans 65 and older — along with tens of millions of younger people who are at higher risk from the coronavirus because of health conditions or their jobs.

Officials described the move as a first step. Boosters will likely be offered even more broadly in the coming weeks or months, including boosters of vaccines made by Moderna and Johnson & Johnson. That, plus continued growth in initial vaccinations, could mean a huge gain in sales and profits for Pfizer and Moderna in particular.

"The opportunity quite frankly is reflective of the billions of people around the world who would need a vaccination and a boost," Jefferies analyst Michael Yee said.

Wall Street is taking notice. The average forecast among analysts for Moderna's 2022 revenue has jumped 35% since President Joe Biden laid out his booster plan in mid-August.

Most of the vaccinations so far in the US have come from Pfizer, which developed its shot with Germany's BioNTech, and Moderna. They have inoculated about 99 million and 68 million people, respectively. Johnson & Johnson is third with about 14 million people.

No one knows yet how many people will get the extra shots. But Morningstar analyst Karen Andersen expects boosters alone to bring in about $26 billion in global sales next year for Pfizer and BioNTech and around $14 billion for Moderna if they are endorsed for nearly all Americans.

Those companies also may gain business from people who got other vaccines initially. In Britain, which plans to offer boosters to everyone over 50 and other vulnerable people, an expert panel has recommended that Pfizer's shot be the primary choice, with Moderna as the alternative.

Andersen expects Moderna, which has no other products on the market, to generate a roughly $13 billion profit next year from all Covid-19 vaccine sales if boosters are broadly authorized.

Potential vaccine profits are harder to estimate for Pfizer, but company executives have said they expect their pre-tax adjusted profit margin from the vaccine to be in the "high 20s" as a percentage of revenue. That would translate to a profit of around $7 billion next year just from boosters, based on Andersen's sales prediction.

J&J and Europe's AstraZeneca have said they don't intend to profit from their Covid-19 vaccines during the pandemic.

For Pfizer and Moderna, the boosters could be more profitable than the original doses because they won't come with the research and development costs the companies incurred to get the vaccines on the market in the first place.

WBB Securities CEO Steve Brozak said the booster shots will represent "almost pure profit" compared with the initial doses.

Drugmakers aren't the only businesses that could see a windfall from delivering boosters. Drugstore chains CVS Health and Walgreens could bring in more than $800 million each in revenue, according to Jeff Jonas, a portfolio manager with Gabelli Funds.

Jonas noted that the drugstores may not face competition from mass vaccination clinics this time around, and the chains are diligent about collecting customer contact information. That makes it easy to invite people back for boosters.

Drugmakers are also developing Covid-19 shots that target certain variants of the virus, and say people might need annual shots like the ones they receive for the flu. All of that could make the vaccines a major recurring source of revenue.

The Covid-19 vaccines have already done much better than their predecessors.

Pfizer said in July it expects revenue from its Covid-19 vaccine to reach $33.5 billion this year, an estimate that could change depending on the impact of boosters or the possible expansion of shots to elementary school children.

That would be more than five times the $5.8 billion racked up last year by the world's most lucrative vaccine — Pfizer's Prevnar13, which protects against pneumococcal disease.

It also would dwarf the $19.8 billion brought in last year by AbbVie's rheumatoid arthritis treatment Humira, widely regarded as the world's top-selling drug.

This bodes well for future vaccine development, noted Erik Gordon, a business professor at the University of Michigan.

Vaccines normally are nowhere near as profitable as treatments, Gordon said. But the success of the Covid-19 shots could draw more drugmakers and venture capitalists into the field.

"The vaccine business is more attractive, which, for those of us who are going to need vaccines, is good," Gordon said.

Top News / World+Biz

Covid -19 / booster / billions / drugmakers

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Excess liquidity Tk2 lakh cr again but banks have little in hand
    Excess liquidity Tk2 lakh cr again but banks have little in hand
  • An Israeli police office inspects the bus that was targeted by gunmen. Photo: BBC
    Several injured in Jerusalem shooting
  • Rising egg prices hit low-income people’s protein intake
    Rising egg prices hit low-income people’s protein intake

MOST VIEWED

  • North Korea's leader Kim Jong Un greets health workers and scientists struggling with the coronavirus disease (Covid-19) pandemic during a photo session in Pyongyang, North Korea, in this undated photo released on August 10, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS
    North Korea lifts mask mandate, distancing rules after declaring Covid victory
  • A motorist passes by a mural of frontline workers against coronavirus at RK Puram in New Delhi on July 25. Delhi’s Covid-19 recoveries have outstripped new cases on almost all days this month barring a few exceptions, after ramped-up containment and testing efforts over the past month or so. (Sanchit Khanna / HT Photo)
    Delhi to enforce mask mandate again after spurt in Covid cases
  • A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell
    US CDC no longer recommends students quarantine for Covid-19 exposure
  • In this file photo taken on March 2, 2019, Kim Yo Jong, sister of North Korea's leader Kim Jong Un, attends a wreath-laying ceremony at Ho Chi Minh Mausoleum in Hanoi. Photo: Hindustan Times
    Kim Jong Un's sister warns Seoul of 'retaliation' over Covid
  • North Korean leader Kim Jong Un speaks at a politburo meeting of the Worker's Party on the country's coronavirus disease (COVID-19) outbreak response in this undated photo released by North Korea's Korean Central News Agency (KCNA) on May 21, 2022. KCNA via REUTERS
    North Korea declares victory over Covid, suggests leader Kim had it
  • Workers wearing protective suits arrive to a building under lockdown for compulsory testing, following the coronavirus disease (COVID-19) outbreak in Hong Kong, China January 7, 2022. Photo :Reuters
    Hong Kong cuts Covid quarantine stay for incoming travellers

Related News

  • North Korea lifts mask mandate, distancing rules after declaring Covid victory
  • Bangladesh logs 1 death, 214 Covid cases in 24 hours
  • S Korea expresses regret over N Korea's 'groundless claim' over Covid, threats
  • Nepal battles 'Twindemic' as swine flu wreaks havoc amid rising Covid cases
  • 1 Covid death, 198 cases reported in a day

Features

Toes and talons of Shikra. Photo; Enam Ul Haque

Shikra: A leopard with wings!

22h | Panorama
Photo: Noor-A-Alam

Around the world in 10 days: A chance to taste global cuisines

21h | Food
Lobbyists float ludicrous arguments to prevent tobacco control act amendment

Lobbyists float ludicrous arguments to prevent tobacco control act amendment

1d | Panorama
Will US-China tensions boil over?

Will US-China tensions boil over?

22h | Panorama

More Videos from TBS

Eggs are selling at record prices

Eggs are selling at record prices

12h | Videos
Dollar price increase affecting Karnaphuli tunnel construction

Dollar price increase affecting Karnaphuli tunnel construction

12h | Videos
Climate crisis a blessing in disguise to them

Climate crisis a blessing in disguise to them

13h | Videos
Growing rice crisis shows how important food self-sufficiency is for Bangladesh

Growing rice crisis shows how important food self-sufficiency is for Bangladesh

14h | Videos

Most Read

1
Dollar crisis: BB orders removal of 6 banks’ treasury chiefs 
Banking

Dollar crisis: BB orders removal of 6 banks’ treasury chiefs 

2
Photo: Collected
Transport

Will Tokyo’s traffic model solve Dhaka’s gridlocks?

3
Representational Image. Photo: Collected
Bangladesh

Air passengers should plan extra commute time to airport: DMP

4
Arrest warrant against Habib Group chairman, 4 others 
Crime

Arrest warrant against Habib Group chairman, 4 others 

5
File Photo: State Minister for Power, Energy and Mineral Resources Nasrul Hamid
Energy

All factories to remain closed once a week under rationing system

6
Ambassador of Switzerland to Bangladesh Nathalie Chuard. Photo: Courtesy
Bangladesh

Bangladesh never asked for particular info from Swiss bank: Ambassador

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net